Loading...
XSHE300653
Market cap486mUSD
Jan 10, Last price  
19.89CNY
1D
-1.68%
1Q
-12.11%
IPO
140.99%
Name

Yantai Zhenghai Bio-Tech Co Ltd

Chart & Performance

D1W1MN
XSHE:300653 chart
P/E
18.68
P/S
8.62
EPS
1.06
Div Yield, %
3.03%
Shrs. gr., 5y
-0.03%
Rev. gr., 5y
13.93%
Revenues
414m
-4.52%
59,296,05777,376,968105,304,734128,132,520150,622,517182,782,114215,543,620279,807,036293,281,582400,175,251433,224,730413,652,710
Net income
191m
+2.98%
8,515,11815,767,28933,660,49042,492,17845,470,11161,669,55485,815,067107,386,387118,333,984168,552,584185,436,805190,957,573
CFO
180m
-3.92%
034,383,49430,791,51245,739,64249,249,89765,473,42077,466,025103,477,376118,432,079166,134,014187,838,040180,477,811
Dividend
Jun 14, 20240.8018 CNY/sh
Earnings
Apr 22, 2025

Profile

Yantai Zhenghai Biotechnology Co., Ltd. engages in the research and development, production, and marketing of regenerative medical materials in China. It offers bone repair material, a partially deproteinised bone prepared from cancellous bones of calves after a series of treatment, such as decellularization and degreasing; oral cavity repair membrane line of products, which are used to treat defects of shallow oral cavity's soft tissue; and bio-membrane line of products that are used in neurosurgery to repair cerebral dura mater defect under the Heal-All brand name. The company also provides skin repair membrane line of products to repair wounds in dermal layer under the Heal-Full brand name. Yantai Zhenghai Biotechnology Co., Ltd. was founded in 2003 and is based in Yantai, China.
IPO date
May 16, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
413,653
-4.52%
433,225
8.26%
Cost of revenue
170,932
211,749
Unusual Expense (Income)
NOPBT
242,721
221,476
NOPBT Margin
58.68%
51.12%
Operating Taxes
27,438
26,671
Tax Rate
11.30%
12.04%
NOPAT
215,283
194,804
Net income
190,958
2.98%
185,437
10.02%
Dividends
(108,000)
(105,600)
Dividend yield
2.07%
1.70%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
25,150
Long-term debt
Deferred revenue
9,124
9,961
Other long-term liabilities
Net debt
(675,276)
(592,360)
Cash flow
Cash from operating activities
180,478
187,838
CAPEX
(31,877)
Cash from investing activities
(86,130)
Cash from financing activities
(108,005)
FCF
200,883
173,718
Balance
Cash
675,188
616,702
Long term investments
89
808
Excess cash
654,594
595,849
Stockholders' equity
679,445
695,690
Invested Capital
302,596
294,749
ROIC
72.08%
71.09%
ROCE
25.18%
24.70%
EV
Common stock shares outstanding
180,149
144,873
Price
29.02
-32.51%
43.00
-3.40%
Market cap
5,227,914
-16.08%
6,229,518
-21.95%
EV
4,552,638
5,637,157
EBITDA
263,237
240,580
EV/EBITDA
17.29
23.43
Interest
Interest/NOPBT